levobupivacaine hydrochloride: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
levobupivacaine hydrochloride: clinical details
Prescribing considerations
- Use only where trained staff, monitoring and resuscitation facilities are immediately available.
- Review cardiovascular function, liver disease, pre-existing neurological disease, frailty and acute illness.
- Prevent unintended intravascular or intrathecal administration using appropriate technique.
- Prolonged epidural exposure needs careful benefit–risk assessment because reported neurological injury has been more severe with extended use.
- Consider sodium content in patients requiring sodium restriction.
Contraindications and cautions
- Hypersensitivity to levobupivacaine, another amide local anaesthetic or a formulation excipient
- Intravenous regional anaesthesia (Bier block)
- Severe hypotension, including cardiogenic or hypovolaemic shock
- Paracervical block in obstetrics
- General contraindications to the proposed regional anaesthetic technique
Monitoring
- Blood pressure, heart rate, ECG, oxygenation, ventilation and consciousness
- Sensory and motor block, pain control and signs of unintended high spinal block
- Neurological or cardiac features of local-anaesthetic systemic toxicity
- Neurological function and bladder or bowel symptoms during epidural use
- Catheter, pump and insertion site during epidural infusion
Clinical pharmacology
Levobupivacaine is the S-enantiomer of bupivacaine and a long-acting amide local anaesthetic. It predominantly inhibits voltage-gated sodium channels, with additional effects on potassium and calcium channels. It is highly protein-bound and extensively metabolised in the liver, principally through CYP3A4 and CYP1A2 pathways.
Formulation and product differences
- The selected 2.5 mg/ml ampoule is a clear, colourless solution for injection or infusion supporting surgical anaesthesia, epidural pain management and a specified paediatric nerve block.
- The selected 1.25 mg/ml bag is a clear, colourless solution for continuous epidural infusion only, licensed for postoperative pain and labour analgesia in adults.
- Both selected products contain sodium; the stated concentration differs slightly.
- Ampoules are single-use. Infusion bags are for single epidural use and should be used only if clear and intact.
levobupivacaine hydrochloride preparations and strengths
Solution for infusion
Route: Intravenous
Strengths: 1.25 mg/mL
Injection
Route: Parenteral
Strengths: 2.5 mg/mL, 5 mg/mL, 7.5 mg/mL, 25 mg/10 mL, 50 mg/10 mL, 75 mg/10 mL
levobupivacaine hydrochloride interactions
The anaesthetist should review all medicines because some combinations may increase toxicity or alter levobupivacaine metabolism.
Other local anaesthetics or related amide medicines
Neurological and cardiovascular toxic effects may be additive.
Mexiletine and class III antiarrhythmics
Their cardiac and local-anaesthetic-like effects may add to those of levobupivacaine.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.